FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

スタックライブラリ

Nootropic Triple Stack

Cognitive Enhancementadvanced

83

シナジー

83
Share
ペプチド

3

平均日用量mcg

72,129

レベル

advanced

追加

May 17, 2026

概要

The Nootropic Triple Stack is designed for serious long-term cognitive optimization — combining Semax''s acute BDNF upregulation with Dihexa''s synaptogenesis and NAD+''s mitochondrial support to drive neuroplasticity, synaptic density, and cellular energy simultaneously. Semax provides the immediate BDNF increase — stimulating existing neurons to grow new connections, improving signal transmission, and protecting against neurodegeneration. As the most acutely potent BDNF-upregulating compound available, Semax creates the biological environment in which new learning and synaptic formation are most likely to occur. Dihexa is a hexapeptide derived from angiotensin that demonstrates extraordinary potency for HGF/Met signaling — a pathway crucial to synaptogenesis (the formation of new synaptic connections). Animal studies showed cognitive improvements in Alzheimer''s models at doses described as "several orders of magnitude more potent than BDNF." Dihexa works over longer timeframes than Semax and is taken less frequently — it builds new synaptic architecture over weeks rather than enhancing acute performance. NAD+ (nicotinamide adenine dinucleotide) is the foundational energy molecule for every cell in the body. Brain neurons are among the most metabolically demanding cells, and NAD+ decline with age directly impairs their function. IV or subcutaneous NAD+ supplementation restores cellular energy production, supports DNA repair, and activates sirtuins — the longevity proteins involved in cognitive aging. NAD+ also synergizes with BDNF signaling, providing the cellular energy required to support the synaptic growth that Semax and Dihexa promote. This stack is administered across different timeframes: Semax daily (acute BDNF), Dihexa three times weekly (chronic synaptogenesis), NAD+ weekly (mitochondrial restoration). It represents a comprehensive, layered approach to long-term cognitive enhancement rather than acute performance.

投与プロトコル

Semax

Every day· intranasal

Semaxについて詳しく読む →

600 mcg

1回の投与あたり

Dihexa

3x per week· oral or topical

Dihexaについて詳しく読む →

100 mcg

1回の投与あたり

NAD+

Once per week· IV or subcutaneous

NAD+について詳しく読む →

500,000 mcg

1回の投与あたり

目標と証拠

NeuroplasticityMemory and learningSynaptogenesisNeuroprotectionLong-term cognitive health
証拠ランク:動物実験

警告

  • Dihexa has minimal human data. NAD+ IV should be administered by a qualified provider. This is an advanced protocol requiring careful monitoring.

Comments

Sign in to join the discussion

注意: このスタックはコミュニティから提出され、研究用のみです。Peptide Contactsは提出されたスタックの安全性や効果性を確認していません。使用するペプチドプロトコル前に常に資格のある医療専門家に相談してください。